Review Article

Unraveling Rare Diseases: A Review of Gaucher Disease, Noonan Syndrome, and Laron Syndrome

Pimple Advay Arun [1], Mrs. Ambekar Sayali. S[2]
[1]Govindrao Nikam College of Pharmacy, Mumbai University, Sawarde, Chiplun, Maharashtra, 415606, India.
[2]Assistant professor, Department of Pharmaceuticals, Govindrao Nikam College of Pharmacy, Sawarde, Chiplun, Maharashtra 415606, India.
***Corresponding author's E-mail:** advaypimple246810@gmail.com

Received: 09-03-2025; **Revised:** 28-05-2025; **Accepted:** 06-06-2025; **Published online:** 15-06-2025.

ABSTRACT

Despite being uncommon on its own, rare diseases pose serious problems for patients, healthcare systems, and pharmaceutical research when taken as a whole. Three different rare genetic disorders—Gaucher disease, Noonan syndrome, and Laron syndrome—are examined in this article. A lack of the glucocerebrosidase enzyme causes Gaucher disease, which causes fatty substances to build up in different organs. Noonan syndrome, a RAS opathy caused by mutations in the RAS/MAPK signaling system, manifests as a variety of symptoms, such as developmental delays, heart problems, and unique facial traits. Laron syndrome causes short height and metabolic problems due to growth hormone insensitivity. Examining the illnesses' epidemiology, pathophysiology, clinical manifestations, diagnostic methods, and therapeutic approaches, the overview underscores the intricacies and continuous progress in the field of rare disease research and therapy.

Keywords: Rare diseases, Genetic disorders, Diagnosis, Treatment, Pathophysiology, Clinical presentation, Gaucher disease, Noonan syndrome, Laron syndrome, Enzyme replacement therapy, Growth hormone, IGF-1, RAS/MAPK pathway, Personalized medicine, Research.

INTRODUCTION

Orphan diseases, often known as rare diseases, present serious difficulties for patients and the pharmaceutical industry. Even though each of these illnesses is uncommon on its own, together they affect millions of individuals globally. The situation is made more difficult by the absence of a single, globally recognized definition that is consistent across nations.

The tiny patient population for uncommon diseases is one of the main obstacles to discovering treatments for them. Pharmaceutical firms may be discouraged from investing in research and development due to the limited market size, as the high expenditures associated with it may not be justified by the possible financial rewards. Furthermore, it can be quite challenging to get participants for clinical studies, which makes it more difficult to collect enough data to warrant regulatory approval.

Furthermore, nothing is known about the fundamental causes and mechanisms of a great deal of rare disorders. Finding suitable objectives for clinical trials and creating focused medicines may be difficult due to this lack of scientific understanding. The difficulties encountered in medication development can be exacerbated by the intricacy of these disorders, which frequently call for creative solutions and specialist knowledge.

Despite these challenges, tremendous strides have been made recently because of developments in personalized medicine, genetic research, and patient-researcher collaboration with pharmaceutical corporations. In order to guarantee that people with uncommon diseases have access to efficient and reasonably priced therapies, there is still more work to be done.

There are particular difficulties in choosing the right clinical trial objectives for uncommon disorders. The discovery of relevant metrics of therapy effectiveness can be impeded by a number of factors, including small patient groups, various disease presentations, varying disease progression rates, and a lack of scientific understanding.

Regulatory bodies may encourage the use of diagnostics or surrogate endpoints and recognize the need to accelerate drug development for uncommon diseases. When standard endpoints are unavailable or inconvenient, these substitute measurements may be useful. Researchers may be able to expedite the assessment of novel treatments by utilizing surrogate endpoints, which are oblique measurements of clinical benefit, or biomarkers, which are biological indications of disease activity.

To guarantee these alternative endpoints' dependability and applicability to the intended patient population, it is imperative to thoroughly verify them.

The Impact of Rare Disease –

Patients and families: Patients and their families may have financial, emotional, and physical hardships as a result of rare diseases, which can have a significant influence on their life.

Healthcare systems: The identification and treatment of uncommon diseases might be difficult for these systems to handle because they call for specific knowledge and funding.

Research & development: Because rare diseases have small patient populations and few financial incentives, developing novel medicines for them can be difficult.

Taking on the problems posed by rare diseases: Despite these obstacles, there has been a notable

advancement in our knowledge of and ability to treat rare diseases in recent years. The lives of those impacted by these disorders are being improved by researchers and healthcare professionals through developments in customized medicine, genetic research, and cooperative initiatives.

The following are some essential tactics for overcoming the difficulties presented by rare diseases:

Enhanced knowledge: Increasing knowledge about uncommon illnesses can aid in better early detection and treatment accessibility.
Supporting for research: Improving patient outcomes requires supporting research into the origins, identification, and management of uncommon diseases.
Patient advocacy: When it comes to fighting for the interests and rights of people with rare diseases, patient advocacy groups can be quite helpful.

GAUCHER DISEASE

Introduction

A genetic condition known as Gaucher disease is brought on by a glucocerebrosidase enzyme deficiency. This enzyme is essential to the body's breakdown of fatty compounds. These fatty compounds (glucocerebroside) accumulate in the liver, spleen, and bone marrow when it is absent or malfunctioning.
Glucocerebroside buildup causes a number of issues, such as:
• **Spleen and liver enlargement**: The function of these organs may be impacted by their enlargement.

• **Bone problems:** These are frequently the initial indications of a disease. They may consist of bone death, fractures, and discomfort.

Essentially, Gaucher disease is a hereditary disorder that mostly affects the liver, spleen, and bones due to an accumulation of fatty substances caused by an enzyme malfunction [1] Click or tap here to enter text.. This accumulation happens as a result of the body's insufficient levels of two vital substances: the helper protein saposin C and the enzyme glucosylceramidase. Together, these two aid in the breakdown of glucosylceramide, a fatty material. This fatty material builds up in cells, primarily immune system cells, when they malfunction [2].

Gaucher was the first to recognize and characterize aberrant cells in the spleen of individuals suffering from the illness that would subsequently bear his name. These are fatty substance-filled macrophages, now called Gaucher cells [3].

A class of hereditary illnesses known as lysosomal storage diseases (LSDs) are brought on by lysosomal storage defects. Cells include microscopic organelles called lysosomes that digest out waste materials.

What takes place in LSDs?

• **Enzyme deficiency:** The majority of the time, LSDs are caused by the body not having an enzyme that is necessary for breaking down particular drugs.

• **Build-up:** These compounds accumulate in the cells and harm them when the proper enzyme isn't present.

• **Transport problems:** The transporters that remove trash from lysosomes might occasionally cause problems instead of the enzymes.[4]

2. Epidemiology

Approximately 1 in 75,000 individuals have the rare genetic condition known as Gaucher disease. It results from a deficiency in glucocerebrosidase, an enzyme that is present in lysosomes. The accumulation of fatty materials in the body is caused by this enzyme deficiency.[5]

3. Pathophysiology

3.1. Accumulation of Glucosylceramides

A glucocerebrosidase enzyme deficiency leads to the metabolic illness known as Gaucher disease. The breakdown of this enzyme is necessary for the metabolism of glucocerebroside, a material that resembles fat. Glucocerebroside accumulates in the body when the enzyme is lacking, mostly in the liver, spleen, and bone marrow. The appearance of Gaucher disease-affected cells is distinct. Within, there are structures known as "Gaucher cells" that house tiny, tube-shaped compartments. When isolated, glucocerebroside, the chemical that is producing this accumulation, also has a similar tubular form. When processed with specific procedures, these tubes become apparent, even if they are hard to see in typical tissue samples [6]. The bone marrow is the main organ affected by Gaucher disease. Here, aberrant, fatty-filled cells known as "Gaucher cells" build up and displace healthy bone marrow cells.

3.2. Phenotypes of Gaucher disease

A defective gene that causes dangerous fats to accumulate in the body is the cause of type 1 Gaucher disease (GD1). Problems with organs, blood cells, and bones result from this accumulation. By eliminating a different gene involved in fat digestion, researchers have been able to alleviate the symptoms in mice carrying the GD1 mutation. Additionally, they found evidence that a certain molecule that resembles fat may be involved in bone loss in GD1 patients.[7]

A highly rare and severe variant of the ailment known as type 2 Gaucher disease begins during the first six months of life. Babies of this type suffer from severe brain disorders like convulsions and muscle stiffness, as well as generalized issues like enlarged livers and spleens. Unfortunately, there's no effective treatment, and most children with this type don't survive past the age of two.[1]

Compared to Type 2, Type 3 Gaucher illness is less severe, allowing people to live past their early years. These people nevertheless continue to have neurological issues [8]. A

complicated disorder with a broad spectrum of symptoms is GD3. Patients can endure modest to severe physical symptoms and varied degrees of neurological disorders. Two primary subtypes exist:

• **Type 3a:** This refers to a neurological disorder known as progressive myoclonic epilepsy together with less severe bodily symptoms.

• **Type 3b:** This includes more serious physical issues together with oculomotor apraxia [9], a neurological condition that affects eye movement.



Figure 1: Gaucher Disease symptoms

Table 1: Phenotype of Gaucher Disease

Type	Symptoms	Severity	Survival Rate
Type 1	Enlarged liver, spleen, and bone problems	Mild to moderate	Generally good
Type 2	Severe brain issues, seizures, muscle stiffness, enlarged liver and spleen	Severe	Poor (most children do not survive past age 2)
Type 3	Neurological complications, including progressive myoclonic epilepsy or oculomotor apraxia	Variable (mild to severe)	Varies

4. Clinical Presentations

Clinically, Gaucher illness is characterized by a broad spectrum of phenotypic diversity, manifesting as anything from death in pregnancy to asymptomatic elderly people. Traditionally, the condition has been classified into three sorts, depending on the frequency and the existence of development of the neurological symptoms. Type 1 non-neuronopathic Gaucher disease is by far the most prevalent. On the other hand, type 2 of acute neuronopathic Gaucher disease is more usual; it begins within a few months of birth and causes a rapidly worsening neurologic deterioration. There are numerous signs and symptoms associated with type 3 chronic neuronopathic Gaucher disease. [10]

4.1. Type-1 Gaucher Disease

The most prevalent type of Gaucher disease, which affects 90–95% of people in North America and Europe, is type 1. This type does not cause neurological issues in its members. Clinical representation can range greatly, from early-life severe symptoms to no discernible problems. Gaucher disease is typically identified in patients between the ages of 10 and 20. For individuals with Gaucher disease type 1, the ICGG Gaucher Registry records vital information about them, such as the date of diagnosis, the size of their spleen and liver, the state of their blood, and the state of their bones [11]. Prior research on adult patients with Gaucher disease was conducted. Though many persons with the syndrome are known to develop it in childhood, there was a lack of information regarding particular cases involving youngsters. This new study uses data analysis from a large number of pediatric patients to better understand the signs and course of Gaucher disease [12].



Figure 2: Type 1 Gaucher disease

4.2. Type-2 Gaucher Disease

A rare and severe form of Gaucher disease, type 2 affects kids between three and six months of age. It affects the nerve system as well as the body, leading to symptoms like neck and body stiffness, trouble swallowing, and problems with the muscles in the eyes. These symptoms are good markers of this illness, as are other symptoms including stiff muscles and a tight jaw. These babies experience severe feeding issues, respiratory distress, and developmental delays. Seizures, an enlarged spleen, and low blood platelet counts are common symptoms. Regretfully, children suffering from this illness usually do not live past the age of two (3) . Type 2 Gaucher disease babies frequently have unique facial traits. These include petite noses, extremely large eye spacing, and atypical ear shapes. These face features are frequently linked to various health issues like weak muscles and tight joints. [13]



Figure 3: Type 2 Gaucher Disease

4.3. Type-3 Gaucher Disease

Gaucher disease type 3 is a more complicated but less severe variation of the illness. It impacts the nervous system as well as the body, in contrast to Type 1. Symptoms can range widely, ranging from mild to severe. While some Type 3 sufferers primarily deal with physical symptoms similar to those observed in Type 1, others face neurological concerns like seizures, trouble moving, or trouble thinking. These neurological symptoms might deteriorate with time and frequently start out slowly [3].

4.4. Skeletal manifestations of Gaucher disease

Gaucher disease frequently causes bone issues. They have a substantial effect on a patient's quality of life even if they are not usually connected to the intensity of other symptoms. Although the precise origins of these bone problems are yet unknown, a number of variables, such as aberrant cell accumulation in the bone marrow, low bone density, inadequate blood supply to the bones, and slowed bone repair, are probably involved. Pain, fractures, and other consequences may result from these issues [1]. Gaucher disease causes a variety of bone issues. Bone problems can occur in persons even in the absence of other symptoms or overt indications of the disease. It is essential to assess the health of the bones in all newly diagnosed individuals. The largest database on Gaucher disease patient bone issues has been compiled by the Gaucher Registry.

Numerous bone issues can arise from Gaucher disease.

• **Osteomyelitis:** An infection of the bone that needs to be treated right away.

• **Erlenmeyer flask deformity:** Usually asymptomatic, this is a broadening of the ends of several bones.

• **Osteopenia:** Reduced bone mass, which raises the possibility of fractures.

• **Osteosclerosis:** An abnormal hardening of the bone tissue that is frequently painful.

• **Osteonecrosis:** A very painful and incapacitating disorder when bone tissue dies from a lack of blood supply.

Imaging methods such as MRI and X-rays can identify certain bone issues [14].

5. Diagnosis of Gaucher disease

Gaucher disease patients frequently receive a diagnosis years after the onset of symptoms. Due of their tendency to develop gradually, uncommon diseases frequently have this problem. Sometimes the diagnosis of Gaucher disease is made while looking into other illnesses. Gaucher cells may be discovered through tests, for instance, if there are anomalous blood cell counts or if the liver or spleen are enlarged.

Doctors analyse the activity of a specific enzyme (acid β-glucosidase) in skin or blood cells to confirm the diagnosis. Genetic testing for the GBA gene may occasionally reveal additional details on the particular form of Gaucher disease[15].

5.1. GCase Activity

Confirming a GCase enzyme deficiency is a necessary step in the diagnosis of Gaucher disease. Testing on cultured skin cells or blood cells can be used for this. Dried blood spots are used in a simple but less precise approach. Although it requires more validation, flow cytometry examination of blood monocytes is a more dependable choice.

Testing for saposin C deficiency should be taken into consideration in rare instances where GCase levels are normal but additional data points to Gaucher disease, particularly when chitotriosidase levels are quite high. The PSAP gene is examined in order to diagnose this illness.

In general, a number of tests as well as a thorough assessment of the symptoms, blood markers, and genetic variables are needed to diagnose Gaucher disease [3].

5.2. Mutations and Polymorphism-Defined Mutations

Patients suffering from Gaucher illness have been shown to have over 300 distinct genetic variants. The disease may result from these mutations altering the GBA gene's structure or function. Recombination with a nearby comparable gene results in some of these mutations. Gaucher disease diagnosis requires locating these mutations.

Initially, a small number of known mutations were found by scientists using a technique called PCR. For Ashkenazi Jewish patients, this worked well; for other patients, particularly those with more severe manifestations of the condition, it did not work as well.

Gaucher patients now have many more mutations identified thanks to advances in sequencing technologies. This has increased the disease's diagnostic accuracy, especially in populations that are not Jewish [15].

6. Treatment of Gaucher disease

While some people with Gaucher disease require treatment, continuous monitoring is necessary for others. After treatment begins, it typically lasts a lifetime. Enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) are the two primary strategies. The goal is to begin treatment before to the onset of serious complications, which may include liver and lung damage, an enlarged spleen, bone issues such as necrosis and fractures, and other incapacitating illnesses.

• **Enzyme replacement treatment (ERT):** This involves intravenous infusions to replace the absent enzyme. This is the most popular treatment for Gaucher disease and is useful in lowering the accumulation of toxic chemicals in the body.

ERT has significantly improved the lives of many patients and transformed the treatment of Gaucher disease.



Figure 4: Enzyme Replacement Therapy

Currently, imiglucerase, velaglucerase alfa, and taliglucerase alfa are the available ERT choices. These treatments function by replenishing the deficient enzyme and minimizing the accumulation of toxic materials within the body.

The visceral features of Gaucher disease type 1, such as an enlarged liver and spleen and low blood cell counts, have been demonstrated to respond very well to ERT.

• **Substrate reduction therapy (SRT):** This entails taking drugs that prevent the accumulation of the material associated with Gaucher disease. Although this treatment is more recent, it has had encouraging outcomes in slowing the disease's progression.

The patient's age, general health, and the severity of the disease all influence the treatment plan that is selected. To evaluate the efficacy of treatment and identify any new problems, routine monitoring is necessary [3].

NOONAN SYNDROME

1. Introduction

A hereditary disorder called Noonan syndrome affects several bodily components. Individuals with Noonan syndrome frequently have characteristic facial traits, like low-set ears, a tiny chin, and wide-set eyes. They might also be low in size, have learning challenges, and endure developmental delays. Furthermore, congenital heart problems such as hypertrophic cardiomyopathy, atrial septal defects, and pulmonary stenosis are common in people with Noonan syndrome. Because of the autosomal dominant pattern of inheritance, an individual only requires one copy of the mutant gene to get ill. Noonan syndrome is thought to affect between 1 in 1000 and 1 in 2500 persons[16].

Dr. Jacqueline Noonan initially reported nine individuals with a range of symptoms, including heart issues, low stature, strange facial features, intellectual incapacity, droopy eyelids, undescended testes, and skeletal anomalies in 1963. This was the first description of the condition. One essential signaling system that aids in cell communication and response to outside stimuli is the **RAS-MAPK pathway**. This pathway, which is important in controlling cell growth, development, survival, and metabolism, is triggered by a variety of chemicals, including growth factors, cytokines, and hormones.

Put another way, it can be likened as a network of communication that exists within cells, facilitating the reception and processing of external messages. For cells to operate normally, this route is necessary [17]. A class of developmental illnesses known as RASopathies is brought on by mutations in the genes that regulate the RAS/MAPK signaling pathway. The growth and development of cells depend on this route. More than 20 genes have been connected to RASopathies thus far.

RASopathies, to put it simply, are a group of illnesses brought on by issues with a certain cellular signaling system. These factors have an impact on cell growth and development, which might result in different developmental diseases. Noonan syndrome and Noonan

syndrome with multiple lentigines (LEOPARD syndrome) are two of the most well-known RASopathies. Some characteristics of these illnesses are similar, including heart issues, cognitive decline, developmental delays, and an elevated risk of cancer [18]. SHP2 gene mutations are the main cause of the RASopathies Noonan syndrome and Noonan syndrome with multiple lentigines. SHP2 is a protein that is present in mitochondria and is implicated in the RAS/MAPK signaling pathway.

Cells' energy-producing powerhouses are called mitochondria. Reactive oxygen species (ROS), which they also produce, have the potential to impact organ development. It is unclear how SHP2 interacts with mitochondria and how this influences the generation of ROS and the development of organs.

SHP2 can interact with elements of the mitochondrial oxidative phosphorylation (Ox Phos) pathway, according to the study. This implies that SHP2 might be involved in controlling how well mitochondria function and how much energy they produce [19].

1.1 The RAS/MAPK Pathway

One signaling mechanism that aids in cell communication and response to outside stimuli is the RAS/MAPK pathway. It is essential to the development and proliferation of cells. Disruption of this route can result in various health issues, including cancer.

Numerous disorders can result from mutations in the RAS/MAPK pathway-related genes. These mutations can impact many tissues and organs and can be inherited or acquired.

The following are a few disorders linked to RAS/MAPK pathway mutations:

• **Cancer:** Numerous cancer forms, such as lung, colon, and pancreatic cancer, have mutations in the RAS gene.

• **RASopathies:** More than 400,000 Americans suffer from this category of developmental abnormalities.

• **Neurological disorders:** Autism and other neurological problems have been linked to abnormal RAS activity.

A family of genes known as the RAS gene family regulates the proliferation of cells. Mutations in any of the four RAS genes—HRAS, NRAS, and the two splice variants of KRAS, KRAS4a and KRAS4b—can result in cancer and developmental abnormalities. These genes share a similar structure, yet they also contain some unique characteristics.

Signals received from sources outside the cell activate the RAS genes. Growth factors, which attach to particular cell surface receptors, are the source of these signals. The RAS genes become active and stimulate cell growth in response to the activation of these receptors [17].

1.2. Noonan Syndrome (NS) and Noonan Syndrome with Multiple Lentigines (NSML)

A moderately common genetic disorder, Noonan syndrome affects 1 in 2000–2500 babies. Dr. Jacqueline Noonan gave the initial description of it in 1963. Because this ailment is inherited in an autosomal dominant form, an individual only has to have one copy of the mutant gene [18]. Numerous physical characteristics, such as peculiar facial traits, cardiac issues, small stature, developmental delays, undescended testes, and an elevated risk of blood illnesses and hormone imbalances, are associated with Noonan syndrome.

Diagnosing Noonan syndrome can be challenging due to its resemblance to other genetic diseases and the wide variety of genetic mutations that can cause it. This is particularly true for those who don't show all of the typical symptoms or weaker symptoms of the illness [20]. The PTPN11 gene is frequently mutated in order to generate Noonan syndrome and Noonan syndrome with multiple lentigines (LEOPARD syndrome). These disorders can also result from mutations in other genes, like RAF1 and BRAF. These illnesses have some similarities but also differ greatly, which can be attributed to the enormous variation in the individual genetic alterations.

A variety of symptoms are shared by LEOPARD syndrome and Noonan syndrome. These include of odd facial traits, cardiac issues, developmental delays, and a higher chance of developing specific illnesses. On the other hand, many lentigines (little brown patches on the skin), café-au-lait spots, and an increased risk of cardiac issues and hearing loss are characteristics of LEOPARD syndrome [18].

2. Natural history

For an average of 12 years, 112 people with Noonan syndrome were followed up on in this study. At the time of evaluation, the majority of participants were adults, with an average age of 25.3 years. The long-term health results of these people were the main focus of the investigation.

Important conclusions:

• **Height:** Adults who have Noonan syndrome are often smaller than usual in height. Women were typically 1.53 meters (5 feet 0 inches) tall, compared to men's 1.70 meters (5 feet 7 inches).

• **Developmental delays:** Language development and academic achievement were often delayed in those with Noonan syndrome.

• **Cardiac issues:** A considerable proportion of patients experienced cardiac issues, such as hypertrophic cardiomyopathy and pulmonary stenosis. These issues raise the possibility of mortality and may necessitate continuing medical care.

• **Additional health concerns:** Blood clots, thyroid disorders, and diabetes were among the other health difficulties associated with Noonan syndrome patients.

• **Mortality:** Heart issues were among the many reasons of death in the study, accounting for 9% of the total deaths.

The research additionally furnished details regarding the particular obstacles encountered by persons with Noonan syndrome:

• **Food issues:** A number of infants with Noonan syndrome had food issues throughout infancy, which may have contributed to their delayed growth and development.

• **Difficulties in the classroom:** A considerable portion of people with Noonan syndrome needed extra help in the form of tutoring or specialized education.

• **Employment:** A lot of people with Noonan syndrome are successful in their employment in spite of the difficulties they encounter. Sixty percent of the people in this sample who were out of school worked full-time.

All things considered; this study offers insightful data regarding the long-term health consequences of people with Noonan syndrome. It emphasizes how crucial it is for these people to receive ongoing medical care, especially in light of their heart health. The research also highlights the need for more assistance in fields like work and education[16].

3. Functional and Pathophysiological Effects of NS and NSML Mutations on Mitochondria and Energy Metabolism

3.1. PTPN11/SHP2

Protein SHP-2 is present in all tissues and cells. Its structure is comparable to that of another protein known as SHP-1. Both proteins start out with two SH2 domains and finish with a phosphatase domain.

These proteins bind to other proteins with the aid of SH2 domains. The phosphatase domains of SHP-2 and SHP-1 are activated when these domains attach to particular locations on other proteins. These proteins' activation enables them to strip other proteins of their phosphate groups, potentially altering the function of those other proteins.

SHP-1 and SHP-2 are often not particularly active. This is because their SH2 domains are inhibiting their action. These domains become more active when they attach to other proteins. This shows that SHP-2 and SHP-1 can change their structure and become more active through the binding of SH2 domains to other proteins.

SHP2 mutations have the ability to boost the protein's activity. This may result in issues with cell signaling and accelerate the onset of illness. For instance, SHP2 activity is increased ten-fold by the D61G mutation and twenty-fold by the D61Y mutation. These mutations have been linked to a variety of illnesses, such as leukemia and Noonan syndrome. Microbiota also contains SHP2. This implies that it might serve further purposes in these structures that produce energy[18].

3.2. KRAS and NRAS

KRAS, NRAS, and HRAS are the three primary members of the RAS gene family. These genes play a role in controlling the division and proliferation of cells. Numerous health issues, such as Noonan syndrome and cardiofaciocutaneous syndrome, can result from mutations in these genes.

The conversion of GDP to GTP activates RAS proteins. The GEFs and GAPs control this process. Upon activation, RAS proteins engage in protein-protein interactions to trigger signaling pathways that regulate several physiological functions, including cell proliferation.

Certain proteins can stay perpetually active because to mutations in the RAS genes. This may result in unchecked cell proliferation and exacerbate illnesses including cancer and developmental problems [20]. KRAS gene mutations are comparatively uncommon in cardiofaciocutaneous syndrome and Noonan syndrome. They are frequently linked to severe symptoms when they are present. Even those who share the same KRAS mutation, however, exhibit a wide spectrum of symptoms, underscoring the intricacy of the ways in which these mutations impact development.

KRAS mutations contribute significantly to the onset and severity of these illnesses, even though they are less frequent than mutations in other genes, such PTPN11. Moreover, family planning and genetic counselling may be affected by the discovery of KRAS mutations in these illnesses [21]. The protein's function is impacted by mutations in the KRAS gene that result in cardiofaciocutaneous syndrome and Noonan syndrome.

3.3. SOS1

The RAS protein, which is essential for cell growth and development, is regulated by the gene SOS1. Developmental abnormalities such as Noonan syndrome can be caused by mutations in SOS1.

The PH domain, the REM domain, and the Cdc25 domain are among the areas of the protein that are impacted by the bulk of SOS1 mutations. These mutations have the potential to change the protein's structure and function, which would boost the RAS protein's activity.

People who have mutations in SOS1 typically exhibit a unique set of symptoms. In addition to the typical aberrant growth of skin and hair, these patients may also exhibit milder cognitive abnormalities and facial features resembling those of cardiofaciocutaneous syndrome.

SOS1 mutations contribute significantly to the onset and severity of these illnesses, even though they are less frequent than mutations in other genes, such PTPN11. Given the wide range of symptoms seen in people with KRAS mutations, more research is necessary to determine the precise pathways via which these mutations contribute to the development of cardiofaciocutaneous syndrome and Noonan syndrome.

In summary, cardiofaciocutaneous syndrome and Noonan syndrome are largely caused by mutations in SOS1. Numerous developmental issues, such as irregular skin and hair growth, cognitive impairments, and cardiac malformations, can result from these mutations. Even

though the precise processes via which SOS1 mutations cause these disorders are not entirely understood, current studies are giving important new information on how this gene functions in human development and illness [20].

3.4. CBL

One gene that controls cell division and proliferation is called CBL. Numerous disorders, including Noonan syndrome, can result from mutations in CBL.

A protein that aids in the breakdown of other proteins is encoded by CBL. Cell signaling regulation depends on a process known as ubiquitination. This mechanism can be hampered by mutations in CBL, which can result in aberrant cell proliferation.

PI3K/AKT is one of the signaling pathways in which CBL is engaged. The growth and survival of cells depend on this route. This system may be disrupted by mutations in CBL, which could result in unchecked cell proliferation and aid in the onset of illnesses. More recent studies indicate that CBL may be more crucial to cell function than previously believed. This is due to the fact that CBL regulates more than simply receptor tyrosine kinases; it is engaged in a greater variety of cellular functions. These results emphasize the role of CBL in healthy development as well as the possible repercussions of CBL dysfunction [20].

4. Diagnosis

A genetic condition called Noonan syndrome is typified by a range of physical characteristics. Though some of these characteristics may last into maturity, newborns and early children have the greatest visibility of them.

Facial features:

- Large head with a small face
- Wide-set eyes
- Droopy eyelids
- Low-set ears
- Short neck with excess skin
- Full lips
- Prominent nasolabial folds in adults

Body features:

- Pectus carinatum (chest protruding outward)
- Pectus excavatum (chest caving inward)
- Wide-spaced nipples
- Rounded shoulders
- Scoliosis
- Joint contractures
- Abnormal forearm carrying angles



Figure 5: Pectus excavatum



Figure 6: Pectus carinatum

Other features:

- Heart problems
- Developmental delays
- Learning difficulties
- Short stature
- Blood clotting problems

Early diagnosis of Noonan syndrome is crucial since it can lead to better results from treatment. Physical therapy for developmental delays, medicines to treat other symptoms, and surgery for heart problems are possible forms of treatment [22].

5. Clinical features

5.1. GROWTH

Usually, newborns with Noonan syndrome are of average size. Nonetheless, individuals could appear heavier because of extra fluid in their bodies. Children with Noonan syndrome typically grow slower than average as they get older. They might also develop their bones more slowly than anticipated. While Noonan syndrome patients often have

normal growth hormone levels, some may also have slightly raised levels of somatomedin, a growth factor.

Furthermore, more specific information regarding the differences in growth patterns between boys and girls with Noonan syndrome has been made available by recent studies. Healthcare professionals can use this information to keep an eye on the development of kids with Noonan syndrome and to intervene appropriately when needed.

It's crucial to remember that people with Noonan syndrome can still grow to a normal adult height even though their growth may be delayed. To guarantee the best results, however, early intervention and growth monitoring are essential [23].

5.2. CARDIAC

Heart issues are common in those who have Noonan syndrome. Persistent ductus arteriosus, ventricular septal defect, asymmetrical septal hypertrophy, atrial septal defect, and pulmonary valvular stenosis are examples of common defects. Single ventricle, Ebstein's abnormality, mitral valve prolapses, and pulmonary artery branch stenosis are other less frequent abnormalities.

Large Q waves, a negative pattern in the left precordial leads, a large QRS complex, and a left axis deviation can all be seen on an ECG. These results point to a cardiac problem, but more testing could be required to identify the precise kind of malfunction.

Heart issues in Noonan syndrome must be managed with early diagnosis and care. Surgery, medicine, or a combination of the two may be used as a form of treatment. Seeing a cardiologist on a regular basis is crucial for tracking the state of the heart and making any therapy adjustments[24].



Figure 7: Pulmonic stenosis & Ventricular septal defect

5.3. SKELETAL

A number of physical characteristics, such as skeletal abnormalities, deformities of the chest, and abnormalities of the face, are indicative of the genetic disorder Noonan syndrome. Among the salient characteristics are:

• **Chest deformities:** Pectus carinatum, pectus excavatum, wide-set nipples, rounded shoulders.

• **Face features:** High forehead, prominent widow's peak, low-set ears, short neck, wide-set eyes, large lips, and a triangular face shape in adolescence and adulthood.

• **Skeletal anomalies:** improper forearm carrying angles, joint contractures, scoliosis, abnormalities of the vertebrae or sternum, and malocclusion of the teeth [23].

Laron Syndrome

Introduction

An uncommon genetic condition called Laron syndrome (LS), sometimes referred to as primary growth hormone (GH) insensitivity, is typified by a malfunction in the body's response to GH. The growth hormone receptor (GH-R) gene abnormalities that underlie this disorder result in an insensitivity to GH and an inability to engage the signaling pathways that GH typically triggers.

The pituitary gland produces growth hormone (GH), a vital hormone that controls metabolism, growth, and other bodily physiological functions. In order to produce insulin-like growth factor 1 (IGF-1), a crucial mediator of GH's functions, it first binds to the GH receptor (GH-R) on cell surfaces, which subsequently triggers downstream signaling pathways. GH is present in sufficient or even high levels in people with Laron syndrome, but its effects are not adequately mediated by the faulty GH receptors, which results in a lack of IGF-1 synthesis. Consequently, GH's normal growth-promoting effects are significantly compromised.

Due to stunted growth, Laron syndrome is characterized by small stature, which is noticeable in early childhood. Despite the growth limitations, the condition also manifests clinically as distinctive facial traits, delayed bone growth, and normal cerebral development.

Laron syndrome is a distinct kind of growth hormone resistance that sheds light on the intricate processes governing growth control as well as the function of IGF-1 and GH in human development. Improved treatment strategies, such as IGF-1 replacement therapy, which avoids the faulty GH receptor and treats the growth shortage directly, have also resulted from a better understanding of the disorder's genetic foundation and molecular causes [25].

In 1958, three children from a consanguineous Jewish Yemeni immigrant family were brought to the clinic because they had a history of hypoglycemia and dwarfism. A large forehead, tiny facial features, sparse or thin hair, obesity, and underdeveloped genitalia (hypogenitalism) were among the physical traits that set these kids apart. They looked like youngsters with **congenital isolated growth hormone deficiency (IGHD)**, a disorder in which the body produces insufficient amounts of growth hormone (GH), which results in stunted growth and development [26].

The physicians discovered that these patients had abnormally high levels of growth hormone in their blood, even at baseline, with the levels rising much more while they slept, using a recently created radioimmunoassay

designed especially for human growth hormone (hGH). This result showed that although the patients were overproducing growth hormone, the hormone was not having its typical growth-promoting effects. As a result of this observation, a novel genetic disease that was inherited in an autosomal recessive fashion and connected to growth hormone production and/or action was discovered. Similar cases were recorded in other countries after the first results. Originally known as "Laron type dwarfism," the disorder was subsequently dubbed Laron Syndrome [25].

We first looked at two possible causes for this novel illness:

(a) the existence of a faulty hGH molecule with no biological activity

(b) a disorder where the body does not react to hGH correctly, resulting in resistance to its effects.



Figure 8: Lateral view of a 3 year old boy with Laron Syndrome, showing the typical. facial features; frontal bossing, spanse hair, saddle nose, small chin

2. Etiology

In order for Laron Syndrome to appear, a person must inherit two copies of the faulty gene, one from each parent. This is known as an autosomal recessive inheritance pattern. Laron Syndrome is mostly caused by either deletions or mutations in the growth hormone (GH) receptor gene. Impaired growth and other related clinical symptoms follow as a result of the body losing its sensitivity to GH stimulation[27]. The exons that encode the GH receptor's extracellular domain contain the majority of the mutations that have been found thus far. But fewer mutations have been discovered in the areas that control the intracellular and transmembrane domains [28].

To date, over 70 distinct mutations have been found. Only those who are homozygous or compound heterozygous for certain genetic abnormalities exhibit the Laron Syndrome (LS) phenotype [29].

3. Primary growth hormone resistance (insensitivity)

3.1. Growth hormone receptor defects

The condition known as Laron-type dwarfism is brought on by a malfunctioning growth hormone (GH) receptor, which stops the body from reacting to GH as it should. The GH receptor gene, located on the short arm of chromosome 5, is mutated in this disease. Growth failure results from decreased production of insulin-like growth factor-1 (IGF-1) due to defective GH signaling caused by this genetic abnormality[28].

Numerous heterozygous mutations have been identified in patients with Laron Syndrome. Children that are affected usually show delayed skeletal maturity, markedly reduced linear growth, and very small height. Underdeveloped facial bones affect their facial characteristics, and depending on the degree of GH resistance, craniofacial deformities can range from modest to quite apparent.

Progressive obesity, which starts in early life, is another notable feature of Laron Syndrome. An elevated body fat percentage and a specific buildup of adipose tissue in the arms are characteristics of this form of obesity [30].

4. Diagnosis

The diagnosis of Laron Syndrome was established through a combination of clinical assessment and laboratory investigations. Clinically, the affected individuals exhibited characteristic features such as severe short stature, distinctive facial features, and other symptoms commonly associated with GH resistance.

The diagnosis is supported by genetic research, left wrist radiography, basal laboratory testing, IGF-1 generation testing, standard auxology data, and characteristic somatic features. A key finding was the presence of abnormally high serum growth hormone (GH) levels despite the absence of an appropriate physiological response [31]. Normally, GH stimulates the production of insulin-like growth factor-1 (IGF-1), which is essential for growth and development. However, in individuals with Laron Syndrome, the GH receptor is dysfunctional due to genetic mutations, preventing GH from effectively triggering IGF-1 production.

To further assess GH function, an IGF-1 generation test was conducted. In this test, recombinant human GH (rhGH) was administered over several days, and IGF-1 levels were measured on the fifth day. A poor or negligible increase in IGF-1 levels (less than 15 mcg/L) confirmed GH resistance, as the body was unable to respond to GH stimulation effectively.

The combination of elevated GH levels and a blunted IGF-1 response strongly indicated Laron Syndrome, distinguishing it from other forms of growth hormone deficiency or short stature disorders[32].

4.1. IGF-1 generation test

IGF-1 and IGFBP-3 levels rise sufficiently in GH insufficiency, neurosecretory dysfunction, and bio-inactive GH (Kowarski

syndrome), but not sufficiently in Laron Syndrome and idiopathic short stature. An IGF-1 generation test is performed if basal GH is high and IGF-1 is low or normal, or if two GH stimulation tests show elevated GH levels. GH resistance, IGF-1 gene defects, ALS deficiency, liver diseases, malnourishment, and chronic illnesses are some of the causes that can cause low IGF-1 levels.

There are various IGF-1 generation test procedures, most of which include administering growth hormone over a few days and taking blood samples to evaluate IGF-1 and IGFBP-3. It is anticipated that IGF-1 will increase threefold or exceed the upper normal limit. Growth velocity and IGFBP-3 binding are important indicators of GH insufficiency, and studies reveal differing responses in various patient groups. It is unclear how sex hormones may affect GH sensitivity during adolescence; however, the timing of peak IGF-1 levels varies across GH-deficient and control groups [33].

A 7-day testing methodology utilizing both low-dose and high-dose GH injection was proposed by Buckway et al. because brief IGF-1 production tests may produce unclear results and certain patient groups may exhibit overlapping responses. The high-dose test employs 0.05 mg/kg per day of GH, whereas the low-dose test uses 0.025 mg/kg per day. On the eighth day, blood is drawn to determine the levels of IGF-1. When GH insensitivity is defined as a rise in IGF-1 of less than 15 ng/ml, there is some overlap between groups in the low-dose test. But when it comes to identifying GH insensitivity, IGFBP-3 assays show excellent diagnostic accuracy, with a 92% specificity and 100% sensitivity [34].

When bio-inactive growth hormone (Kowarski syndrome) is present, the IGF-1 generation test usually reveals an increase of about 30 ng/ml for IGF-1 and 400 ng/ml for IGFBP-3. Conversely, IGF-1 increases by less than 15 ng/ml and IGFBP-3 stays below 400 ng/ml in patients with Laron-type dwarfism, indicating far weaker responses.

There is no accepted standard for performing and interpreting the IGF-1 generation test, despite the fact that there are several procedures. In the last two years, more than ten different protocols have been utilized, according to a poll of members of the European Society for Pediatric Endocrinology (ESPE). Furthermore, the test's positive predictive value was modest. Its use in making judgments about diagnosis and therapy has thus been deemed restricted [35].

4.2. Genetic studies

Growth hormone (GH) resistance is the main result of mutations in the growth hormone receptor (GHR) gene, which causes Laron syndrome, sometimes referred to as Laron-type dwarfism. The GHR gene, which has ten exons and is roughly 87 kilobases long, encodes a transmembrane protein that is a member of the cytokine receptor family. Three domains make up this receptor's structure:

1. Extracellular Domain is the domain that binds to GH and is encoded by exons 2 through 7.

2.Transmembrane Domain: Exon 8 encodes this domain, which secures the receptor to the cell membrane.

3.Intracytoplasmic Domain: Encoded by exons 9 and 10, this domain transmits signals inside the cell upon GH binding.

GH resistance can result from mutations that alter the GHR gene and impair receptor function. Deletions, nonsense mutations, missense mutations, splice site mutations, and frameshift mutations are examples of these mutations. Notably, the pathophysiology of Laron syndrome is especially affected by mutations in the extracellular domain that hinder GH binding.

The variety of these mutations adds to the variation in Laron syndrome patients' clinical presentations. Accurate diagnosis and possible treatment approaches depend on knowing the precise genetic changes in the GHR gene (36,37).

5. Clinical features

Nine children (two girls and seven boys) between the ages of 2.5 and 11.5 who had been diagnosed with Laron Syndrome based on clinical examination and diagnostic investigations were the subjects of a five-year study that ran from January 2008 to January 2013. Consanguinity, birth weight, neonatal hypoglycemia, the development of short height, family history, and any signs of chronic illness or secondary reasons of growth retardation were among the many aspects of their medical history that were thoroughly examined. To evaluate pubertal development, any genital anomalies, and clinical indicators of growth hormone (GH) deficiency, a thorough physical examination was performed. This involved assessing characteristics such the micropenis, which is characterized as a stretched penile length that is less than two standard deviations (SD) of the age-related mean [38].

A hemogram, renal function tests, and, if required, anti-tissue transglutaminase IgA were performed to rule out chronic disease. In the morning, while the patients were fasting, biochemical tests were conducted. These tests included thyroid function tests (T3, T4, and TSH) using chemiluminescence, as well as measures of Insulin-like Growth Factor-1 (IGF-1) and Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) using the enzyme-linked immunosorbent assay (ELISA). ELISA was also used to measure basal cortisol levels.

To assess GH secretion, a growth hormone (GH) stimulation test was performed. First, ELISA was used to measure the fasting serum GH levels in the morning. After that, a dose of 0.15 mg/m² of clonidine was given orally [39].

6. Treatment

Since 1986, the sole approved treatment for Laron syndrome (LS) has been recombinant insulin-like growth factor 1 (IGF-1) therapy. People with LS have low levels of IGF-1 because their bodies are unable to respond to growth hormone (GH) due to a malfunction in the growth hormone

receptor (GHR). The short stature and metabolic problems that are typical of LS are caused by this deficit [40].

Recombinant IGF-1 therapy circumvents the faulty GH receptor by directly substituting the absent IGF-1. Because they are unable to respond to GH administration, people with LS do not profit from it, in contrast to those with conventional growth problems where GH therapy is successful. Subcutaneous injections of IGF-1, on the other hand, promote growth and metabolic processes that GH would typically control.

Serum levels of growth hormone (GH), growth hormone-releasing hormone (GHRH), and glucose decreased after a single bolus dose of IGF-1.

A daily dose of IGF-1 of 150–220 µg/kg body weight, ideally with the largest meal, produced significant improvements for long-term treatment. Head circumference showed the fastest catch-up development, rising from an average of -3.3 ± 0.9 SD to +0.87 ± 1.8 SD, suggesting substantial brain expansion. In contrast to the more rapid linear growth usually observed in GH-deficient children undergoing GH therapy, the overall height rise was more moderate [41].

IGF-1 treatment affected protein metabolism and decreased blood lipotropin levels. It also promoted erythropoiesis, which raised hemoglobin levels in the blood. Moreover, increased serum testosterone concentrations were linked to IGF-1 treatment [42].

CONCLUSION

Rare disorders like Gaucher disease, Noonan syndrome, and Laron syndrome face particular hurdles in diagnosis, treatment, and research. Improving patient outcomes requires an understanding of the various clinical manifestations, the molecular and genetic causes, and the creation of efficient care plans. For those afflicted by these crippling illnesses, ongoing research developments, especially in personalized medicine and genetic therapies, hold out promise for more individualized and efficient treatments as well as an improved quality of life. To meet the unmet needs of the rare disease community and advance rare disease treatment, more advocacy, increased awareness, and teamwork are still necessary.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Vaccaro AM, Motta M, Tatti M, Scarpa S, Masuelli L, Bhat M, et al. Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting. Hum Mol Genet. 2010 Aug 1;19(15):2987–97.
2. Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Vol. 29, Human Mutation. 2008. p. 567–83.
3. Stirnemann JÔ, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of gaucher disease pathophysiology, clinical presentation and treatments. Vol. 18, International Journal of Molecular Sciences. MDPI AG; 2017.
4. Stirnemann J, Vigan M, Hamroun D, Heraoui D, Rossi-Semerano L, Berger MG, et al. The French Gaucher's disease registry: Clinical characteristics, complications and treatment of 562 patients. Orphanet J Rare Dis. 2012;7(1).
5. Lee RE. THE FINE STRUCTURE OF THE CEREBROSIDE OCCURRING IN GA UCHER'S DISEASE*.
6. Mikosch P, Hughes D. An overview on bone manifestations in Gaucher disease. Wiener Medizinische Wochenschrift. 2010 Dec;160(23–24):609–24.
7. Dekker N, Van Dussen L, Hollak CEM, Overkleeft H, Scheij S, Ghauharali K, et al. Elevated plasma glucosylsphingosine in Gaucher disease: Relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011 Oct 20;118(16).
8. Kraoua I, Sedel F, Caillaud C, Froissart R, Stirnemann J, Chaurand G, et al. A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients. Brain Dev. 2011 Feb;33(2):131–9.
9. Boven LA, Van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol. 2004;122(3):359–69.
10. Grabowski GA, Zimran A, Ida H. Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry. Vol. 90, American Journal of Hematology. Wiley-Liss Inc.; 2015. p. S12–8.
11. Kaplan P, Andersson HC, Kacena KA, Yee JD. The Clinical and Demographic Characteristics of Nonneuronopathic Gaucher Disease in 887 Children at Diagnosis [Internet]. Vol. 160, Arch Pediatr Adolesc Med. 2006. Available from: http://archpedi.jamanetwork.com/
12. Mignot C, Gelot A, Bessières B, Daffos F, Voyer M, Menez F, et al. Perinatal-lethal Gaucher disease. Am J Med Genet. 2003 Jul 30;120 A(3):338–44.
13. Danuta Balicki MD, Ernest Beutler MD. Reviews in Molecular Medicine.
14. Dandana A, Ben Khelifa S, Chahed H, Miled A, Ferchichi S. Gaucher Disease: Clinical, Biological and Therapeutic Aspects. Vol. 83, Pathobiology. S. Karger AG; 2016. p. 13–23.
15. Jane F. Desforges. Gaucher Diesease Review Article by Jane F. Desforges. 1991;
16. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Vol. 381, The Lancet. Elsevier B.V.; 2013. p. 333–42.
17. Bajia D, Bottani E, Derwich K. Effects of Noonan Syndrome-Germline Mutations on Mitochondria and Energy Metabolism. Vol. 11, Cells. MDPI; 2022.
18. Lee I, Pecinova A, Pecina P, Neel BG, Araki T, Kucherlapati R, et al. A suggested role for mitochondria in Noonan syndrome. Biochim Biophys Acta Mol Basis Dis. 2010 Feb;1802(2):275–83.
19. Dard L, Bellance N, Lacombe D, Rossignol R. RAS signalling in energy metabolism and rare human diseases. Vol. 1859, Biochimica et Biophysica Acta - Bioenergetics. Elsevier B.V.; 2018. p. 845–67.
20. Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders. Vol. 25, Best Practice and Research: Clinical Endocrinology and Metabolism. Bailliere Tindall Ltd; 2011. p. 161–79.
21. Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, Koenig R, et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet. 2007 Feb;44(2):131–5.

22. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, et al. Noonan syndrome: Clinical features, diagnosis, and management guidelines. Vol. 126, Pediatrics. 2010. p. 746–59.
23. Allanson JE. Noonan syndrome. Vol. 24, Syndrome of the month Journal of Medical Genetics. 1987.
24. Sanchez-Cascos A. The Noonan Syndrome. Vol. 4, European Heart Journal. 1983.
25. Laron Z, Werner H. Laron syndrome – A historical perspective. Vol. 22, Reviews in Endocrine and Metabolic Disorders. Springer; 2021. p. 31–41.
26. Laron Z. Laron Syndrome (Primary Growth Hormone Resistance or Insensitivity): The Personal Experience 1958-2003. Vol. 89, Journal of Clinical Endocrinology and Metabolism. 2004. p. 1031–44.
27. Adam A, Josefsberg Z, Pertzelan A, Zadik Z, Chemke JM, Laron Z. Pediatrics Occurrence of Four Types of Growth Hormone-Related Dwarfism in Israeli Communities. Vol. 137, European Journal of Eur J Pediatr. 1981.
28. Arlan L. Rosenbloom M. Growth hormone insensitivity: Physiologic and genetic basis, phenotype and treatment. 1999;
29. Kaji H, Nose O, Tajiri H, Takahashi Y, Iida K, Takahashi T, et al. Novel Compound Heterozygous Mutations of Growth Hormone (GH) Receptor Gene in a Patient with GH Insensitivity Syndrome*. 1997.
30. Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N. Body composition in untreated adult patients with Laron syndrome (primary GH insensitivity). Clin Endocrinol (Oxf). 2006 Jul;65(1):114–7.
31. Blum WF, Ranke MB, Catherine Postel-vinay M, Cotterill AM, Hall K, Chatelain PG, et al. Clinical Features and Endocrine Status in Patients with Growth Hormone Insensitivity (Laron Syndrome). 1993.
32. Phanse-Gupte SR, Khadilkar V V., Khadilkar A V. Clinical features and endocrine profile of Laron syndrome in Indian children. Indian J Endocrinol Metab. 2014 Nov 1;18(6):863–7.
33. Kurtoɨlu S, Hatipoglu N. Growth hormone insensitivity: Diagnostic and therapeutic approaches. Vol. 39, Journal of Endocrinological Investigation. Springer International Publishing; 2016. p. 19–28.
34. Buckway CK, Guevara-Aguirre J, Pratt KL, Burren CP, Rosenfeld RG. The IGF-I Generation Test Revisited: A Marker of GH Sensitivity. Vol. 86, The Journal of Clinical Endocrinology & Metabolism. 2001.
35. Coutant R, Dörr HG, Gleeson H, Argente J. Limitations of the IGF1 generation test in children with short stature. Vol. 166, European Journal of Endocrinology. 2012. p. 351–7.
36. Savage MO, Hwa V, David A, Rosenfeld RG, Metherell LA. Genetic defects in the growth hormone-IGF-I axis causing growth hormone insensitivity and impaired linear growth. Vol. 2, Frontiers in Endocrinology. 2011.
37. Arman A, Ozon A, Isguven PS, Coker A, Peker I, Yordam N. Novel Splice Site Mutation in the Growth Hormone Receptor Gene in Turkish Patients with Laron-type Dwarfism. Vol. 21, London Journal of Pediatric Endocrinology & Metabolism. 2008.
38. Teckchandani N, Bajpai M. Penile length nomogram for Asian Indian prepubertal boys. J Pediatr Urol. 2014;10(2):352–4.
39. Coutant R, Dörr HG, Gleeson H, Argente J. Limitations of the IGF1 generation test in children with short stature. Vol. 166, European Journal of Endocrinology. 2012. p. 351–7.
40. Breen JL. The Gynecologist and the older patient. Aspen Publishers; 1988. 420 p.
41. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. 2023.
42. Laron Z, Klinger B. Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). European Journal of Endocrinology. 2022;138:50-56.

For any questions related to this article, please reach us at: globalresearchonline@rediffmail.com
New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com